Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases

References

• Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th ed. Lyon: IARC; 2008. pp. 233–237.
   Google Scholar
• Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351–6357.
   PubMed Web of Science ®Google Scholar
• Dürkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421–427.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Vardiman JW, et al. Hematopathology. Philadelphia, PA: Elsevier Health Sciences; 2010.
   Google Scholar
• Schneider C, Hübinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma. 2002;43:1355–1366.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subset of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013 Jan 23. [Epub ahead of print]
   Web of Science ®Google Scholar
• Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848–858.
   PubMed Web of Science ®Google Scholar
• Pallesen G. The diagnostic significance of the CD30 (Ki-1) antigen. Histopathology 1990;16:409–413.
   PubMed Web of Science ®Google Scholar
• Noorduyn LA, De Bruin PC, Van Heerde P, et al. Relation of CD30 expression to survival and morphology in large cell B cell lymphomas. J Clin Pathol 1994;47:33–37.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997;90:3727–3734.
   PubMed Web of Science ®Google Scholar
• Engelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997;89:2291–2297.
   PubMed Web of Science ®Google Scholar
• Haralambieva E, Pulford KA, Lamant L, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol 2000;109:584–591.
   PubMed Web of Science ®Google Scholar
• Maes B, Anastasopoulou A, Kluin-Nelemans JC, et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30 + anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol 2001;12:853–858.
   PubMed Web of Science ®Google Scholar
• Calaminici M, Piper K, Lee AM, et al. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45:619–624.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 2011;29 (Suppl.): Abstract 8032.
   PubMed Web of Science ®Google Scholar
• Fromm JR, McEarchern JA, Kennedy D, et al. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk 2012;12:280–283.
   PubMed Web of Science ®Google Scholar
• Chen RW, Gopal AK, Smith SE. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011;29 (Suppl.): Abstract 8031.
   Google Scholar
• Wilkins BS. Pitfalls in lymphoma pathology: avoiding errors in diagnosis of lymphoid tissues. J Clin Pathol 2011;64:466–476.
   PubMed Web of Science ®Google Scholar
• Shen Y, Iqbal J, Huang JZ, et al. BCL2 protein expression parallels its mRNA level in normal and malignant B cells. Blood 2004; 104:2936–2939.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200–207.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961–968.
   PubMed Web of Science ®Google Scholar
• Fend F. Classical Hodgkin lymphoma. In: Jaffe ES, Vardiman J, Campo E, et al., editors. Hematopathology. 1st ed. Philadelphia, PA: Elsevier Health Sciences/Saunders; 2011. pp. 454–472.
   Google Scholar
• Medeiros LJ, Elenitoba-Johnson KSJ. Anaplastic large cell lymphoma. Am J Clin Pathol 200;127:707–722.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012;25:968–982.
   PubMed Web of Science ®Google Scholar
• Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011;24:1046–1054.
   PubMed Web of Science ®Google Scholar
• Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23:587–593.
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736–3742.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136–1143.
   PubMed Web of Science ®Google Scholar
• Ott MM, Horn H, Kaufmann M, et al. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients. Leuk Res 2012;36:544–545.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194: 1861–1874.
   PubMed Web of Science ®Google Scholar